Alteogen showed weakness during trading on the 18th, fluctuating around the 370,000 won level. As of 1:56 p.m. that day, Alteogen traded at 370,000 won, down 3,000 won (0.80%) from the previous trading day. Cumulative trading volume exceeded 580,000 shares.

The stock price, which started the session on a strong note, turned lower as sell orders increased. However, the decline remained limited, with trading battles unfolding around the 370,000 won level.

Investor attention that day focused on news related to the company's officially disclosed 'ALT-B4' platform. Alteogen revealed that the first partner of its previously signed ALT-B4 technology export agreement was global pharmaceutical company Sanofi. According to some media reports, the contract was a large-scale technology transfer agreement signed in 2019, with the counterparty undisclosed at the time.

With the identification of Sanofi as the first customer, Alteogen's platform technology competitiveness is being highlighted once again. ALT-B4 is evaluated as a core foundational technology that converts intravenous (IV) injection drugs into subcutaneous (SC) injection forms. Based on this, Alteogen has been continuously expanding its scope of cooperation with global pharmaceutical companies and has been recording consecutive technology export achievements.

The market atmosphere is focusing less on the short-term event of revealing Sanofi and more on future additional technology transfer agreements and the progress of full-scale commercialization. In particular, the potential for expanding collaboration with global big pharma is cited as a key variable that will determine Alteogen's mid- to long-term growth potential.

Meanwhile, while the KOSPI index continues its bullish run by breaking the 9000 level intraday, the KOSDAQ index is showing a weak trend. Amid this, Alteogen is maintaining a steady trend, and investors are closely watching for specific progress in future technology export agreements and development schedules for key pipelines.

[※ This article was written with the assistance of AI. Investment decisions are the responsibility of the investor, and the content included in this article may change depending on market conditions.]